TY  - JOUR 
AU  - Ribera, Josep Maria
AU  - Morgades, Mireia
AU  - Garcia Calduch, Olga
AU  - Sirvent, Maialen
AU  - Buendia, Buenaventura
AU  - Cervera, Marta
AU  - Luzardo, Hugo
AU  - Hernández Rivas, Jesús María
AU  - Sitges, Marta
AU  - García Cadenas, Irene
AU  - Abrisqueta, Pau
AU  - Montesinos, Pau
AU  - Bastos Oreiro, Mariana
AU  - Queipo de Llano, Maria Paz
AU  - Bravo, Pilar
AU  - Torrent, Anna
AU  - Herrera, Pilar
AU  - Garcia Guinon, Antoni
AU  - Vall Llovera, Ferrán
AU  - Serrano, Josefina
AU  - Terol, María José
AU  - Bergua, Juan Miguel
AU  - Garcia Noblejas, Ana
AU  - Barrenetxea, Cristina
AU  - Llorente, Laura
AU  - García Belmonte, Daniel
AU  - Gimeno, Eva
AU  - Cladera, Antonia
AU  - Mercadal, Santiago
AU  - Sancho, Juan Manuel
PY  - 2024
UR  - http://hdl.handle.net/10366/171842
AB  - [EN]High dose-intensive or infusional intermediate-dose immunochemotherapy is highly effective treatment for Burkitt lymphoma irrespective of human immunodeficiency virus (HIV) infection. However, toxicities of these regimens are relevant, especially...
LA  - eng
KW  - Burkitt Lymphoma
KW  - HIV Infections
KW  - Humans
KW  - Young Adult
KW  - Aged
KW  - Middle Aged
KW  - Drug Tapering
KW  - Feasibility Studies
KW  - Prospective Studies
KW  - Prospective Studies
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Cyclophosphamide
KW  - Doxorubicin
KW  - Rituximab
KW  - Feasibility Studies
KW  - Burkitt Lymphoma
KW  - HIV Infections
KW  - Aged
KW  - Prospective Studies
KW  - Young Adult
KW  - Doxorubicin
KW  - Leukemia
KW  - Cyclophosphamide
KW  - Humans
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Middle Aged
TI  - Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial
DO  - 10.3324/haematol.2023.283342
T2  - Haematologica
VL  - 109
M2  - 543
ER  -